Limited evolution of HIV antiretroviral drug resistance-associated mutations during the performance of drug resistance testing

Journal of Acquired Immune Deficiency Syndromes

Volumn 32, Issue 1, 2003, Pages 57-61

  Birch, Chris ^a   Middleton, Tracey ^b   Hales, Gillian ^b   Cooper, David ^b   Law, Matthew ^b   Crowe, Suzanne ^b   Hoy, Jennifer ^b   Emery, Sean ^b  

^a VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

^b NONE

Author keywords

Antiretroviral drug therapy; Drug resistance testing; Evolution in reverse transcriptase and protease; Resistance mutations

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG SENSITIVITY; FEMALE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZATION; VIRUS LOAD; VIRUS MUTATION; VIRUS STRAIN;

EID: 0037236587     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200301010-00008     Document Type: Article

References (15)

1. Durant J, Clevenbergh P, Halfon P, et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 1999;353:2195-9.
2. Baxter JD, Mayers DL, Wentworth DN, et al. A randomised study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. AIDS 2000;14(Suppl):F83-93.
3. Tural C, Ruiz L, Holtzer C, et al. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS 2002;16:209-18.
4. Cohen CJ, Hunt S, Sension M, et al. A randomised trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS 2002;16:579-88.
5. Hirsch MS, Brun-Vezinet F, D'Aquila RT, et al. Antiretroviral drug resistance testing in adult HIV-1 infection. Recommendations of an international AIDS society-USA panel. JAMA 2000;283:2417-26.
6. Devereux HL, Youle M, Johnson MA, et al. Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. AIDS 1999;13(Suppl):F123-7.
7. Verhofstede C, Wanzeele FV, Van Der Gucht B, et al. Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype. AIDS 1999;13:2541-6.
8. Hance AJ, Lemiale V, Izopet J, et al. Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy. J Virol 2001;75:6410-7.
9. Land S, McGavin C, Birch C, et al. Reversion from zidovudine resistance to sensitivity on cessation of treatment. Lancet 1991;338:830-1.
10. Boucher CA, van Leeuwen R, Kellam P, et al. Effects of discontinuation of zidovudine treatment on zidovudine sensitivity of human immunodeficiency virus type 1 isolates. Antimicrob Agents Chemother 1993;37:1525-30.
11. Schinazi R, Larder B, Mellors J. Mutations in retroviral genes associated with drug resistance: 2000-2001 update. Int Antiviral News 2001;8:65-91.
12. Middleton T, Smith D, Larder B, et al. Baseline antiretroviral drug susceptibility influences treatment response in patients receiving saquinavir-enhancing therapy. HIV Clin Trials 2001;2:445-52.
13. Shulman NS, Machekano RA, Shafer RW, et al. Genotypic correlates of virologic response to stavudine after zidovudine monotherapy. J Acquir Immune Defic Syndr 2001;27:377-80.
14. Romano L, Venturi G, Bloor S, et al. Broad nucleoside-analogue resistance implications for human immunodeficiency virus type 1 reverse-transcriptase mutations at codons 44 and 118. J Infect Dis 2002;185:898-904.
15. Hertogs K, Verbiest W, De Vroey V, et al. Continuing drug pressure did not alter drug resistance profiles between screening and baseline visits in the prospective trial VIRA3001. Antiviral Ther 2000;5(Suppl 3):126-7.